Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Lenhard

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
BMC Cancer|January 1, 2014
Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancerMiriam Lenhard, Sabine Heublein, Christiane Kunert-Keil, et al.
Archives of Gynecology and Obstetrics|December 19, 2008
Relapse and survival in early-stage ovarian cancerS Miriam Lenhard, A Bufe, C Kümper, et al.
Clinical Chemistry and Laboratory Medicine|September 20, 2011
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian massesMiriam Lenhard, Petra Stieber, Linda Hertlein, et al.
Archives of Gynecology and Obstetrics|October 24, 2012
A retrospective investigation of women's experience with breast reconstruction after mastectomyNina Ditsch, Ingo Bauerfeind, Andrea Vodermaier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 5, 2010
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) studyM Corona Gainford, Anna Tinker, Jonathan Carter, et al.
Human Immunology|October 9, 2002
Prolongation of small bowel allograft survival with a sequential therapy consisting of a synthetic MHC class II peptide and temporarily low-dose cyclosporine AChristoph Otto, Martin Gasser, Ana Maria Waaga-Gasser, et al.
Histology and Histopathology|January 1, 2013
Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8Darius Dian, Miriam Lenhard, Doris Mayr, et al.
Oncology Letters|December 4, 2012
Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinomaNina Ditsch, Doris Mayr, Miriam Lenhard, et al.
BMC Cancer|December 18, 2012
Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patientsVerena Engelstaedter, Sabine Heublein, Anamur Lan Schumacher, et al.
Oncotarget|May 27, 2015
Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-statusMatthias Dürst, Heike Hoyer, Christoph Altgassen, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
BMC Cancer|January 1, 2014
Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancerMiriam Lenhard, Sabine Heublein, Christiane Kunert-Keil, et al.
Archives of Gynecology and Obstetrics|December 19, 2008
Relapse and survival in early-stage ovarian cancerS Miriam Lenhard, A Bufe, C Kümper, et al.
Clinical Chemistry and Laboratory Medicine|September 20, 2011
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian massesMiriam Lenhard, Petra Stieber, Linda Hertlein, et al.
Archives of Gynecology and Obstetrics|October 24, 2012
A retrospective investigation of women's experience with breast reconstruction after mastectomyNina Ditsch, Ingo Bauerfeind, Andrea Vodermaier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 5, 2010
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) studyM Corona Gainford, Anna Tinker, Jonathan Carter, et al.
Human Immunology|October 9, 2002
Prolongation of small bowel allograft survival with a sequential therapy consisting of a synthetic MHC class II peptide and temporarily low-dose cyclosporine AChristoph Otto, Martin Gasser, Ana Maria Waaga-Gasser, et al.
Histology and Histopathology|January 1, 2013
Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8Darius Dian, Miriam Lenhard, Doris Mayr, et al.
Oncology Letters|December 4, 2012
Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinomaNina Ditsch, Doris Mayr, Miriam Lenhard, et al.
BMC Cancer|December 18, 2012
Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patientsVerena Engelstaedter, Sabine Heublein, Anamur Lan Schumacher, et al.
Oncotarget|May 27, 2015
Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-statusMatthias Dürst, Heike Hoyer, Christoph Altgassen, et al.
Pageof 4